What are the harms and benefits of using pegylated liposomal doxorubicin in women with recurrent epithelial ovarian cancer, alone or in combination with other drugs? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
Year: 2024
Type: review
Abstract: This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2023, Issue 7. Art. No.: CD006910. DOI: 10.1002/14651858.CD006910.pub3.
Source: Journal of Modern Oncology
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $679
OpenAlex ID: W4404248215